Efficacy of a moxidectin versus ivermectin in subjects infected by Strongyloides stercoralis

ISRCTN ISRCTN11983645
DOI https://doi.org/10.1186/ISRCTN11983645
Secondary identifying numbers N/A
Submission date
04/04/2016
Registration date
04/04/2016
Last edited
07/02/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Strongyloides stercoralis, commonly referred to as threadworms, is a type of parasitic worm that infects the large intestines. S. stercoralis can cause a range of gastrointestinal (gut) symptoms, including nausea, pain and diarrhoea, and long-term infections can lead to disabling complications such as anaemia, stunted growth and slow mental development. S. stercoralis infections are very common in south East Asia and affect mainly adults. At the moment the most effective drug against the infection is ivermectin (a medication used to treat a range of different parasitic infections). The aim of this study is to find out whether the medication moxidectin (a drug designed specifically to kill parasitic worms) is active against the worm in the human body.

Who can participate?
Adults with a S. stercoralis infection

What does the study involve?
Participants are randomly allocated to one of two groups. Participants in the first group receive a single dose of 8mg moxidectin. Participants in the second group receive a single dose of 200ug/kg ivermectin. At the start of the study and 21 days after treatment, participants provide stool samples so that the severity of the infection can be measured. Participants are also asked to report any unwanted side-effects from the medications 3, 24, 48 and 72 hours after treatment.

What are the possible benefits and risks of participating?
Participants will benefit from receiving a free medical examination and treatment. There are no risks of participating as the study medications have been used before and no major side effects have been reported.

Where is the study run from?
Local villages in Champasack province (Laos)

When is the study starting and how long is it expected to run for?
December 2015 to June 2016

Who is funding the study?
European Research Council (Belgium)

Who is the main contact?
Prof. Jennifer Keiser

Contact information

Prof Jennifer Keiser
Scientific

Swiss Tropical and Public Health Institute (Swiss TPH)
Socinstr. 57
Basel
4051
Switzerland

Study information

Study designSingle-blind phase 2 randomised parallel trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Community
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet.
Scientific titleEfficacy of moxidectin vs ivermectin against Strongyloides stercoralis infections: a randomised parallel trial
Study objectivesThe aim of this study is to assess the first time the efficacy of oral moxidectin against S. stercoralis infection.
Ethics approval(s)1. Ethical comittee of Northern and Central Switzerland, 07/12/2015, ref: EKNZ UBE-15/103
2. Ministry of Health, National Institute of Public Health, Lao People's Democratic Republic, 11/01/2016, ref: NIOPH/NECHR 075
Health condition(s) or problem(s) studiedStrongyloides stercoralis infection
InterventionSubjects will be randomly assigned to one of the two treatment arms:
Group 1: Participants receive a single dose of ivermectin 200 ug/kg.
Group 2: Participants receive a single dose of moxidectin 8 mg.

Follow up will be carried out 21 days after the treatment and involves the provision of two stool samples.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Moxidectin, ivermectin
Primary outcome measureStrongyloides stercoralis infection status is determined 21 days after treatment using the Baermann method in 2 stool samples.
Secondary outcome measures1. Adverse events are measured through self-reporting 3, 24, 48 and 72 hours after treatment
2. S. stercoralis infection intensity is measured using a larval count in stool samples 21 days after treatment in relation to baseline infection intensity (LRR)
3. O. viverrini and other helminth infection status and intensity is measured using stool samples (Kato Katz method) 21 days after treatment
Overall study start date01/12/2015
Completion date30/06/2016

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants120 infected subjects
Key inclusion criteria1. Aged 18 years or over
2. Infected with S. stercoralis infection
3. Absence of major systemic illnesses
4. Written informed consent signed
Key exclusion criteria1. Abnormal medical conditions or chronic disease
2. Negative diagnostic result for soil-transmitted helminthes infection
3. No written informed consent
4. Recent anthelminthic treatment (past 2 months)
5. Pregnancy
Date of first enrolment21/04/2016
Date of final enrolment06/05/2016

Locations

Countries of recruitment

  • Lao People's Democratic Republic

Study participating centre

National Institute of Public Health
Vientiane
01
Lao People's Democratic Republic

Sponsor information

Swiss Tropical and Public Health Institute (Swiss TPH)
University/education

Socinstr. 57
Basel
4051
Switzerland

ROR logo "ROR" https://ror.org/03adhka07

Funders

Funder type

Research council

European Research Council
Government organisation / National government
Alternative name(s)
ERC

Results and Publications

Intention to publish date30/06/2017
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a peer reviewed journal.
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 15/07/2017 Yes No
Results article results from embedded study 26/03/2018 Yes No

Editorial Notes

07/02/2019: Publication reference added.
19/10/2017: Publication reference added.
11/08/2017: Internal review.
06/07/2017: Internal review.